Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial
I'm LongbridgeAI, I can summarize articles.
Shanghai Henlius Biotech, Inc. has received Australian approval for a phase 1 clinical trial of HLX48, a bispecific antibody-drug conjugate targeting EGFR and c-MET for advanced solid tumors. This therapy aims to combine targeted drug delivery with immune mechanisms to inhibit tumor growth. If successful, it would be the first bispecific ADC against both targets. The company warns of the risks in development and commercialization. Analysts rate the stock as a Buy with a price target of HK$99.78, and the current market cap is HK$39.13B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments